HIMSBy Calypso Research8 min read

Hims and Hers (HIMS) Q4 2025 Earnings Analysis

“Hims & Hers Faces Weighty Concerns with $618M Growth”

Key Takeaways

Hims and Hers (HIMS) reported Q4 2025 earnings with revenue of $618M, representing a +28.4% year-over-year change. The stock moved -0.8% on earnings day.

The bull case: Hims & Hers leverages a diversified, tech-enabled platform across multiple specialties and geographies—anchored by labs, AI, and international scale—to drive durable double-digit growth and expand margins toward its 2030 targets.

The bear case: Regulatory and legal risks around GLP-1s, the capital intensity of international expansion and new initiatives, and a wide guidance range signal that growth may increasingly require heavy reinvestment, limiting margin expansion and raising execution risk.

Financial Highlights

  • Revenue: $618M (+28.4% YoY)
  • Gross Profit: $444M (71.9% margin, -4.9% YoY)
  • Operating Income: $9M (1.5% margin, -2.4% YoY)
  • Net Income: $21M
  • TTM Revenue: $2.3B

Stock Performance

  • Earnings Day Move: -0.8%
  • Year-to-Date: -53.6%
  • 1-Year Return: -69.8%
  • vs. S&P 500 (since earnings): -59.3%
  • vs. Nasdaq (since earnings): -57.0%

View live HIMS data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Hims and Hers's Q4 2025 earnings call:

Sentiment: Mixed

"When you look into the business today, it's important to remember that the majority of our revenue and profitability is driven by offerings outside of weight loss. And really, the amount of patients that actually are on the compounded GLP-1s is actually quite a small minority of the aggregate subscriber base." — Andrew Dudum
"The ticket size for the GLP-1 business is a bit larger than our core business. So the revenue impact as well as the EBITDA impact there that we see is fairly meaningful. But I think that said... the vast majority of the revenue is made from the non-GLP-1 business. As we continue to diversify, we expect that trend to continue." — Yemi Okupe

Capital Intensity, Margin Trajectory, and 2026 EBITDA Guidance Flexibility

Sentiment: Mixed

"We expect 2026 adjusted EBITDA will be between $300 million and $375 million... Our guide provides is the ability and the flexibility to lean into continuing to scale those specialties if we see them achieve promising signs on the unit economic front." — Yemi Okupe
"As you look kind of at the end of 2025, we launched 3 specialties that we feel have the ability to be fairly transformative to the platform... if we see meaningful opportunities for growth in technology, meaningful growth opportunities in new specialties or meaningful growth opportunities in our international markets, we definitely want to take the growth orientation to take them." — Yemi Okupe

International Expansion Strategy and Integration of Eucalyptus / ZAVA / Livewell

Sentiment: Positive

"At the core of it is to target the 10 key most critical markets and to win them handily over the next 12 to 24 months... we have a bold ambition to see the Hims & Hers brand be unified across all of these major markets within the next year or 2 and a North Star of $1 billion plus in incremental international revenue in the next few years as well." — Andrew Dudum
"Assuming the transaction closes, our expectation is that our collective international business will break even within 12 to 18 months, inclusive of Eucalyptus... we expect to take a growth-oriented approach and focus on reaching as many consumers as possible before focusing on the margin expansion efforts, even if that means running certain markets at or near breakeven." — Yemi Okupe

Platform Evolution: Labs, Wearables, AI, and Proactive / Preventative Care Flywheel

Sentiment: Positive

"This is where I think the platform really transitions from focusing on a single treatment to proactive preventative care. I actually think that type of care is in and of itself a new category for Hims & Hers... as people start to realize a platform like Hims & Hers gives you access to what the 1% have and let you take the necessary steps to get ahead of it, it's extremely empowering." — Andrew Dudum
"Ultimately, we think that these investments as they start to come together in 2026, even outer years, have the ability to quickly have positive ROI and ultimately pay off for themselves and become self-funding... whether that's in the form of higher lifetime value... or even just with proactive care being able to unlock new insights to consumers to drive better acquisition efficiency." — Yemi Okupe

Growth Drivers Within Core Hims & Hers Specialties (Ex‑GLP‑1) and Mix Shift

Sentiment: Positive

"We were excited to see the Hims brand growth 30% year-over-year in 2025. And we do believe that we're positioned for continued growth whether that's in the form of newer specialties like testosterone that are rapidly emerging or even as we start to see the benefit from the stronger retention on the daily health offerings in both sexual health and greater assortment in other categories like hair." — Yemi Okupe
"So far, I would say just nearly 10 years of testing out go-to-market strategies, I would say we are incredibly encouraged by the early data. I think we believe that each of those 3 have near-term opportunities to scale to $100 million run rate, just like many of our other winning categories." — Andrew Dudum

Bull Case

Hims & Hers leverages a diversified, tech-enabled platform across multiple specialties and geographies—anchored by labs, AI, and international scale—to drive durable double-digit growth and expand margins toward its 2030 targets.

Bear Case

Regulatory and legal risks around GLP-1s, the capital intensity of international expansion and new initiatives, and a wide guidance range signal that growth may increasingly require heavy reinvestment, limiting margin expansion and raising execution risk.

Looking Ahead

With revenue growing +28.4% year-over-year, the key question is whether Hims and Hers can sustain this growth trajectory, particularly around regulatory / Legal Risk and Durability of the GLP‑1 Weight Loss Business. With operating margins at 1.5%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Hims and Hers's revenue in Q4 2025?

Hims and Hers reported Q4 2025 revenue of $618M, representing a +28.4% year-over-year change.

Did Hims and Hers beat earnings expectations in Q4 2025?

The stock moved -0.8% on earnings day, suggesting the results were roughly in line with market expectations. The current bull case centers on: Hims & Hers leverages a diversified, tech-enabled platform across multiple specialties and geographies—anchored by labs, AI, and international scale—to drive durable double-digit growth and expand margins toward its 2030 targets.

What is the bull case for HIMS stock?

The bull case for HIMS centers on: Hims & Hers leverages a diversified, tech-enabled platform across multiple specialties and geographies—anchored by labs, AI, and international scale—to drive durable double-digit growth and expand margins toward its 2030 targets.

What is the bear case for HIMS stock?

The bear case for HIMS centers on: Regulatory and legal risks around GLP-1s, the capital intensity of international expansion and new initiatives, and a wide guidance range signal that growth may increasingly require heavy reinvestment, limiting margin expansion and raising execution risk.

How has HIMS stock performed since its Q4 2025 earnings?

HIMS moved -0.8% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +59.3% since earnings. Year-to-date, the stock has returned -53.6%.

Browse all 400+ earnings reports →

Learn More

Analyze HIMS in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Hims and Hers and 400+ other stocks, explore the full platform.

Open HIMS on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.